PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer.

Huang, Wei; Qian, Zhengtao; Shi, Yuxin; Zhang, Zheming; Hou, Rui; Mei, Jie; Xu, Junying; Ding, Junli

Huang, Wei; Qian, Zhengtao; Shi, Yuxin; Zhang, Zheming; Hou, Rui; Mei, Jie; Xu, Junying; Ding, Junli.

Affiliation

Huang W; Department of Oncology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Qian Z; Department of Clinical Laboratory, Changshu Medicine Examination Institute, Changshu, 215500, People's Republic of China.
Shi Y; Department of Oncology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Zhang Z; Wuxi School of Clinical Medicine, Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Hou R; Wuxi School of Clinical Medicine, Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Mei J; Department of Oncology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Xu J; Wuxi School of Clinical Medicine, Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Ding J; Department of Oncology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, People's Republic of China.

Pharmgenomics Pers Med ; 16: 747-758, 2023.

Article de En | MEDLINE | ID: mdl-37581119

Mots clés

PSMC2; bioinformatics; biomarker; pancreatic cancer; tumor immunity

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Pharmgenomics Pers Med Année: 2023 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google